色噜噜国产精品视频一区二区,精品国产乱码91久久久久,超级大胆欧美人体免费视频,5g影院天天看天天爽,91精品国产福利在线观看,久久亚洲国产精品五月天婷,久久婷婷国产精品香蕉,日本一区二区三区免费观看,久久精品久久一区二区,久久精品人人槡人妻人人玩

Mitral regurgitation (MR) is a common cardiac valve lesion, developing from primary lesions of the mitral valve or secondary to cardiomyopathies. Moderate or higher severity of mitral regurgitation imposes significant volume overload on the left ventricle, causing permanent structural and functional deterioration of the myocardium and heart failure. Since correction of mitral regurgitation can provide symptomatic relief and halt progressive cardiac dysfunction, transcatheter mitral valve repair technologies are emerging as alternative therapies.

Enlight medical is developing transcatheter mitral valve repair and replacement devices, and its repair device NovoClasp^TM is now in the pivotal clinical study in China.